Igor Meglinski, MSc, PhD, is a Professor in Quantum Biophotonics and Biomedical Engineering at the College of Engineering & Physical Sciences at Aston University (Birmingham, UK). He is a Faculty member in the School of Engineering and Technology at the Department of Mechanical, Biomedical & Design Engineering, and is also associated with the Aston Institute of Photonic Technologies (AIPT) and Aston Research Centre for Health in Ageing (ARCHA). Professor Meglinski’s research interests lie at the interface between physics, medicine and biological sciences, focusing on the development of new non-invasive imaging/diagnostic techniques and their application in medicine & biology, material sciences, pharmacy, food, environmental monitoring, and health care industries. He is Chartered Physicist (CPhys), Chartered Engineer (CEng), Fellow of Institute of Physics, and Fellow of SPIE. Prof. Meglinski is author and co-author over 450 papers published in peer-reviewed scientific journals, proceedings of international conferences, and book chapters, and over 800 presentations at the major international conferences, including about 400 invited lectures, keynote and plenary talks.
This will count as one of your downloads.
You will have access to both the presentation and article (if available).
Our goal is to develop an in vivo method for the non-invasive measurement of cerebral blood flow and CSF circulation by exploiting optical and capacitive sensing techniques simultaneously. We introduce a prototype of a wearable probe that is aimed to be used for long-term brain monitoring purposes, especially focusing on studies of the glymphatic system. In this method, changes in cerebral blood flow, particularly oxy- and deoxyhaemoglobin, are measured simultaneously and analysed with the response gathered by the capacitive sensor in order to distinct the dynamics of the CSF circulation behind the skull. Presented prototype probe is tested by measuring liquid flows inside phantoms mimicking the CSF circulation.
RBC aggregation dynamics in autologous plasma and serum studied with double-channel optical tweezers
There exist several potential optical measurement techniques to be utilised for the purpose. The most desired method would allow the detection of the drugs without using optical biomarkers as a contrast agent. In this case, for non-invasive sensing of the drug in the brain cortex, the drug should have a reasonably strong optical absorption band somewhere in the range between 600 nm and 1700 nm, and not directly coincident with the strong bands of haemoglobin or water. Alternatively, mid-infrared (MIR) range has the potential for invasive drug monitoring techniques.
In this paper, we report the optical properties of several chemotherapy drugs used in CNS lymphoma therapy, such as rituximabi, cyclophosphamide and etoposide. We measured their transmittance and reflectance spectra in near-infrared (NIR) range, particularly 900 nm − 2500 nm, to be considered when choosing the in vivo monitoring method to be developed. The absorption and scattering coefficients were retrieved from the measurements and applying Beer’s law. For the measurement of the sum of total transmission and reflection in NIR range we used integrating sphere with spektralo to enable calculation of the scattering coefficient.
Peer-to-peer Monte Carlo simulation of photon migration in topical applications of biomedical optics
This will count as one of your downloads.
You will have access to both the presentation and article (if available).
View contact details
No SPIE Account? Create one
